Group 1 - The core viewpoint of the article highlights that 毛戈平's stock has seen an increase of nearly 3%, currently trading at 92.6 HKD with a transaction volume of 59.54 million HKD [1] - On February 5, 毛戈平 announced that it received approval from the Hong Kong Stock Exchange to list and trade 228 million H-shares, which are the maximum number of unlisted shares to be converted and listed [1] - Goldman Sachs' research indicates that despite challenges in the overall cosmetics industry, 毛戈平 is expected to outperform the market, with projected compound annual growth rates (CAGR) for sales and net profit reaching 23% and 22% respectively from 2025 to 2027 [1] Group 2 - Shenwan Hongyuan forecasts that 毛戈平's gross merchandise volume (GMV) on Douyin is expected to grow by around 50% in 2025, with both skincare and makeup segments contributing to this growth [1] - The profit growth rate for the company is anticipated to be 35% in 2025, indicating strong performance in the upcoming years [1]

Core Viewpoint - The completion of the H-share full circulation by Fuhong Hanlin marks a significant step in the company's equity structure and capital operations, enhancing liquidity and governance standards while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - A total of 183 million non-listed shares have been converted into H-shares, which will start trading on the Hong Kong Stock Exchange on February 5, 2026 [1] - After the full circulation, the total number of H-shares will increase to 346 million [1] - The full circulation is expected to attract more international investors, benefiting the long-term development of the company and its shareholders [1] Group 2: Product Portfolio and Market Presence - Fuhong Hanlin has 10 products approved for sale in over 60 markets globally [1] - The company has achieved significant milestones in major biopharmaceutical markets, with 4 products receiving FDA approval and 4 products obtaining EMA authorization [1] - The company has a diversified pipeline with over 50 early-stage molecules, demonstrating its commitment to high-quality research and development aligned with international standards [1]

Core Viewpoint - The completion of H-share full circulation by Fuhong Hanlin marks a significant step in the company's equity structure and capital operations, enhancing liquidity and governance standards while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - A total of 183 million non-listed shares were converted into H-shares, which will begin trading on the Hong Kong Stock Exchange on February 5, 2026 [1] - Following the full circulation, the total number of H-shares will increase to 346 million [1] - The full circulation is expected to attract more international investors, benefiting the long-term development and shareholder interests of the company [1] Group 2: Product Portfolio and Market Presence - Fuhong Hanlin has 10 products approved for sale in over 60 markets globally [1] - The company has achieved significant milestones in major biopharmaceutical markets, with 4 products receiving FDA approval and 4 products obtaining EMA authorization [1] - The company has a diversified pipeline with over 50 early-stage molecules, demonstrating its commitment to high-quality research and development aligned with international standards [1]

Core Viewpoint - The completion of the H-share full circulation marks a significant step for the company in terms of equity structure and capital operations, enhancing liquidity and governance while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - The company announced the conversion of 182,645,856 non-listed shares into H-shares, which will start trading on February 5, 2026, increasing the total number of H-shares to 346,074,397 [1] - This move is expected to expand the liquidity of the company's shares listed in Hong Kong and improve market pricing effectiveness and fairness [1] Group 2: Financial Performance and Strategic Development - The company became the first Hong Kong-listed innovative pharmaceutical company to achieve full-year profitability in 2023, driven by product sales [1] - The stable cash flow generated from biosimilars will support ongoing innovation and research and development, as the company transitions into a "Globalization 2.0" development phase characterized by capability building and innovation [1]

Core Viewpoint - The H-share listing model provides a flexible and convenient internationalization path for domestic companies in China, allowing them to leverage international capital markets for financing opportunities and enhancing market liquidity and capital diversification [1] Group 1: Approval Process by China Securities Regulatory Commission (CSRC) - Companies must submit an IPO application to the Hong Kong Stock Exchange (HKEX) and file a registration application with the CSRC within three working days after submission [2][5] - The CSRC focuses on compliance issues, including foreign investment access, corporate governance, and the structure of shareholding [5] - Specific requirements apply to certain categories of companies, such as those planning to list on the Hong Kong Growth Enterprise Market or those issuing preferred shares abroad [3] Group 2: H-share "Full Circulation" - H-share "full circulation" allows domestic shares, which were previously transferable only within China, to be freely traded in the Hong Kong market, enhancing market liquidity and pricing efficiency [6] - There are no restrictions on the number or proportion of shares that can be applied for "full circulation," allowing flexibility based on the company's situation [7] Group 3: Approval Process by Hong Kong Stock Exchange (HKEX) - The listing process typically takes 6 to 9 months, involving document preparation, initial feedback from the HKEX, and a hearing before the listing committee [10][11] - Companies must ensure that financial information is accurately disclosed in the H-share prospectus, particularly regarding quarterly reports [12] Group 4: Corporate Governance - The HKEX requires listed companies to establish audit, remuneration, and nomination committees, with independent non-executive directors to enhance governance transparency [13] - New corporate governance codes will take effect in July 2025, introducing term limits for independent directors and promoting gender diversity on boards [13] Group 5: Share Trading Restrictions - Core connected persons, such as directors and major shareholders, are prohibited from trading shares in the four working days prior to the listing unless exempted by the HKEX [14] - Existing shareholders wishing to participate in the IPO must obtain approval from the HKEX, with specific exemptions for minority shareholders [15] Group 6: Conclusion - The H-share listing presents a significant opportunity for domestic companies to expand their international presence and access diverse capital markets, emphasizing the importance of understanding relevant policies and approval processes [16]

Group 1 - A total of 11 companies have received approval for overseas issuance or domestic unlisted shares "full circulation" registration, all listed on the Hong Kong Stock Exchange [1] - Companies such as Huajin Technology and Guanghe Technology, which are already listed on A-shares, plan to issue up to 102 million shares and 54.39 million shares respectively in Hong Kong [1] - New Qi'an, Youzhiyou Biotechnology, Tongyuan Kang Medical, Ruike Biotechnology, and Fuhong Hanlin are transitioning their unlisted shares to H-shares, with respective share amounts of 41.08 million, 68.01 million, 4.608 million, 14.2 million, and 18.3 million [1] Group 2 - Lantu Automotive, a new energy brand under Dongfeng, aims to list on the Hong Kong Stock Exchange through an introduction method without new share issuance, targeting over 150,000 cumulative deliveries by 2025 [1] - Aixin Yuanzhi, backed by chip tycoon Yu Renrong and companies like Meituan and Tencent, has shipped 165 million chips since its establishment five years ago, with a projected revenue CAGR of 206.8% from 2022 to 2024, although it has not yet achieved profitability [1] - Huaxida, a smart home solution provider for enterprise clients, plans to issue up to 72.96 million shares in Hong Kong and convert 190 million shares to H-shares [2] - Feisuo Innovation, an online DTC network solution provider, aims to issue up to 104 million shares in Hong Kong after a previous attempt to list on the Shenzhen main board failed, also converting 360 million shares to H-shares [2]

Core Viewpoint - The company has received a filing notice from the China Securities Regulatory Commission regarding the full circulation of H-shares, allowing for the conversion of unlisted shares into H-shares [1] Group 1 - The company has completed the filing for the conversion of a total of 142 million unlisted shares held by 28 shareholders into H-shares [1] - The filing notice is valid for 12 months starting from January 13, 2026 [1] - The company will apply to the Hong Kong Stock Exchange for the approval of the listing and trading of the relevant H-shares [1]

Core Viewpoint - The company has received a filing notice from the China Securities Regulatory Commission regarding its plan to implement full circulation of H-shares, allowing for the conversion of domestic shares into H-shares for trading on the Hong Kong Stock Exchange [1] Group 1 - The company plans to convert a total of 41.0823 million domestic shares, which represents approximately 42.7% of the company's total issued share capital as of the announcement date [1] - The filing notice from the China Securities Regulatory Commission will be valid for 12 months starting from January 26, 2026 [1] - The company intends to apply for approval from the Hong Kong Stock Exchange for the listing and trading of these H-shares on the main board [1]

Core Viewpoint - Sinopec Engineering (02386) has received a filing notice from the China Securities Regulatory Commission regarding the implementation of full circulation of H-shares [1] Group 1 - The company has completed the filing for the conversion of 219,980,000 domestic shares held by China Petroleum Group into 219,980,000 H-shares [1] - The validity period of the filing notice is 12 months [1] - The company will apply to the Hong Kong Stock Exchange for the approval of the listing and trading of these H-shares on the main board [1]

智通财经APP讯，中石化炼化工程(02386)公布，董事会已于近日收到中国证监会就公司实施 H股全流通 出具的备案通知书。根据备案通知书，公司已就H股全流通(内容有关中国石油集团所持的219,980,000 股内资股转换为219,980,000股H股)向中国证监会完成备案。备案通知书的有效期为12个月。公司将向 香港联交所申请批准该等H股于香港联交所主板上市及买卖。 ...